Physician profile
Conner Chan
NPI 1962669515
$8,910.54
in general payments reported to CMS, 2019-2025
28 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $565 · 2021: $1,069 · 2022: $1,326 · 2023: $1,574 · 2024: $1,279 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.79 |
| Education | $192.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,588.47 | 2019-2025 | Aklief, Oracea, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,141.98 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Janssen Biotech, INC. | $885.96 | 2019-2025 | Tremfya |
| Biofrontera INC. | $549.31 | 2019 | |
| Dermavant Sciences, INC. | $413.38 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $397.07 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $396.25 | 2020-2024 | Dupixent |
| Leo Pharma INC. | $370.48 | 2019-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $363.85 | 2024-2025 | Zoryve |
| Abbvie INC. | $319.96 | 2019-2025 | |
| Ucb, INC. | $316.01 | 2020-2025 | Bimzelx |
| Journey Medical Corporation | $309.75 | 2019-2024 | |
| Keswick Pharmaceuticals LLC | $291.16 | 2019 | |
| Sun Pharmaceutical Industries INC. | $284.04 | 2020-2024 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $263.81 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $263.18 | 2022-2025 | Sotyktu |
| Pfizer INC. | $170.60 | 2019-2023 | |
| Amgen INC. | $168.46 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $122.16 | 2021-2023 | |
| Epi Health, LLC | $100.37 | 2019-2022 | |
| Dermira, INC. | $74.25 | 2019-2021 | |
| Organon LLC | $32.26 | 2025 | Vtama |
| Almirall LLC | $21.93 | 2023 | Seysara |
| Celgene Corporation | $13.98 | 2019 | |
| Mission Pharmacal Company | $13.69 | 2019 | |
| Vyne Pharmaceuticals INC. | $13.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2019 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conner Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.